U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula CH5N3.CHNS
Molecular Weight 118.161
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of GUANIDINE THIOCYANATE

SMILES

SC#N.NC(N)=N

InChI

InChIKey=ZJYYHGLJYGJLLN-UHFFFAOYSA-N
InChI=1S/CH5N3.CHNS/c2-1(3)4;2-1-3/h(H5,2,3,4);3H

HIDE SMILES / InChI

Molecular Formula CHNS
Molecular Weight 59.09
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula CH5N3
Molecular Weight 59.0705
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Guanidine is a small basic compound. Guanidine stimulates the neuromuscular junction presynaptically by inhibiting voltage-gated potassium (Kv) channels, leading to the enhanced release of acetylcholine in the synaptic cleft. This stimulatory effect of guanidine underlies its use in the therapy for the neuromuscular diseases. The hydrochloride salt of guanidine was approved by FDA for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert.

CNS Activity

Curator's Comment: The study was performed on rats.

Originator

Curator's Comment: Original article: A. Strecker, Liebigs Ann. Chem. 1861, 118, 151-177.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
GUANIDINE HYDROCHLORIDE

Approved Use

Guanidine is indicated for the reduction of the symptoms of muscle weakness and easy fatigability associated with the myasthenic syndrome of Eaton-Lambert. It is not indicated for treating myasthenia gravis. The Eaton-Lambert syndrome is ordinarily differentiated from myasthenia gravis by the usual association of the syndrome with small cell carcinoma of the lung, but myography may be necessary to make the diagnosis.

Launch Date

-9.5463362E11
PubMed

PubMed

TitleDatePubMed
Expression and refolding of full-length human TIMP-1.
2001
Evolution and physiological roles of phosphagen systems.
2001
Stabilization of hen egg white lysozyme by a cavity-filling mutation.
2001 Feb
[Discovery of cis-preference of aromatic N-methylamides and its application to molecular constructions].
2001 Feb
Erythrocyte transketolase activity and guanidino compounds in hemodialysis patients.
2001 Feb
Apparent two-state tendamistat folding is a sequential process along a defined route.
2001 Feb 16
Solid-phase guanidinylation as a diversification strategy of poly-L-proline type II peptide mimic scaffolds.
2001 Feb 22
Efficient gene transfection by bisguanylated diacetylene lipid formulations.
2001 Feb 23
Collision-induced dissociation of ring-opened cyclic depsipeptides with a guanidino group by electrospray ionization/ion trap mass spectrometry.
2001 Jan
Cellular responses of NG108-15 and SK-N-MC lines to sweet and bitter tastants as measured by extracellular acidification rates.
2001 Jan 1
Folding-unfolding of goat alpha-lactalbumin studied by stopped-flow circular dichroism and molecular dynamics simulations.
2001 Jan 1
The PD...(D/E)XK motif in restriction enzymes: a link between function and conformation.
2001 Jan 16
Achieving stability and conformational specificity in designed proteins via binary patterning.
2001 Jan 19
Probing conformational changes in the estrogen receptor: evidence for a partially unfolded intermediate facilitating ligand binding and release.
2001 Mar
Matrix proteins from insect pliable cuticles: are they flexible and easily deformed?
2001 Mar 15
Structural alterations and inhibition of unisite and multisite ATP hydrolysis in soluble mitochondrial F1 by guanidinium chloride.
2001 Mar 20
Dramatic stabilization of an SH3 domain by a single substitution: roles of the folded and unfolded states.
2001 Mar 30
The pro domain of beta-secretase does not confer strict zymogen-like properties but does assist proper folding of the protease domain.
2001 Mar 30
Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: insights into kinase mechanism.
2001 Mar 30
Osmolytes protect mitochondrial F(0)F(1)-ATPase complex against pressure inactivation.
2001 Mar 9
The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase.
2001 Mar 9
Guanidino-containing drugs in cancer chemotherapy: biochemical and clinical pharmacology.
2001 May 15
Patents

Sample Use Guides

Initial dosage is usually between 10 and 15 mg/kg (5 to 7 mg/pound) of body weight per day in 3 or 4 divided doses. This dosage may be gradually increased to a total daily dosage of 35 mg/kg (16 mg/pound) of body weight per day or up to the development of side effects.
Route of Administration: Oral
In Vitro Use Guide
Mice spinal cord neurons were treated with guanidine at concentrations between 100 nM and 100 mM. At 100 mM induced a membrane depolarization of 10 to 25 mV and rapidly and reversibly reduced GABA responses: 23.9% decrease of GABA responses was obtained with 10 mM guanidine and complete inhibition was observed with 100 mM). It also significantly reduced Glycine response at 10 mM.
Substance Class Chemical
Created
by admin
on Fri Dec 15 19:39:29 UTC 2023
Edited
by admin
on Fri Dec 15 19:39:29 UTC 2023
Record UNII
GCA2EU297U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
GUANIDINE THIOCYANATE
Common Name English
BUFFER AVL
Brand Name English
GUANIDINIUM ISOTHIOCYANATE
Systematic Name English
GUANIDINE ISOTHIOCYANATE
Systematic Name English
GUANIDINIUM THIOCYANATE
Systematic Name English
NSC-2119
Code English
Code System Code Type Description
NSC
2119
Created by admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
PRIMARY
FDA UNII
GCA2EU297U
Created by admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
PRIMARY
ECHA (EC/EINECS)
209-812-1
Created by admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
PRIMARY
WIKIPEDIA
Guanidine thiocyanate
Created by admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
PRIMARY
EPA CompTox
DTXSID6060478
Created by admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
PRIMARY
CAS
593-84-0
Created by admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
PRIMARY
PUBCHEM
65046
Created by admin on Fri Dec 15 19:39:29 UTC 2023 , Edited by admin on Fri Dec 15 19:39:29 UTC 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE